Technical Analysis for QURE - uniQure N.V.

Grade Last Price % Change Price Change
F 30.06 -1.89% -0.58
QURE closed down 1.89 percent on Friday, October 15, 2021, on 41 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Oct 25
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical QURE trend table...

Date Alert Name Type % Chg
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup -1.89%
NR7 Range Contraction -1.89%
Wide Bands Range Expansion -1.89%
Oversold Stochastic Weakness -1.89%
Outside Day Range Expansion -0.82%
Wide Bands Range Expansion -0.82%
Oversold Stochastic Weakness -0.82%
Older End-of-Day Signals for QURE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % 3 days ago
Fell Below Previous Day's Low 3 days ago
Down 1% 3 days ago
Possible NR7 4 days ago
Rose Above 10 DMA 4 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


uniQure N.V. Description

uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Diseases Clinical Development Genetics Gene Therapy Parkinson's Disease Applied Genetics Metabolic Disease Hemophilia Gene Delivery Lipoprotein Adeno Associated Virus Treatment Of Hemophilia Acute Intermittent Porphyria Alipogene Tiparvovec Glybera Hemophilia B Lipase Lipoprotein Lipase Deficiency

Is QURE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 52.19
52 Week Low 25.8
Average Volume 624,732
200-Day Moving Average 33.12
50-Day Moving Average 31.63
20-Day Moving Average 32.55
10-Day Moving Average 30.74
Average True Range 1.21
ADX 28.62
+DI 12.74
-DI 24.30
Chandelier Exit (Long, 3 ATRs) 35.17
Chandelier Exit (Short, 3 ATRs) 33.54
Upper Bollinger Bands 37.58
Lower Bollinger Band 27.51
Percent B (%b) 0.25
BandWidth 30.94
MACD Line -0.72
MACD Signal Line -0.36
MACD Histogram -0.3564
Fundamentals Value
Market Cap 1.34 Billion
Num Shares 44.5 Million
EPS -2.80
Price-to-Earnings (P/E) Ratio -10.75
Price-to-Sales 368.82
Price-to-Book 9.86
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.16
Resistance 3 (R3) 31.24 30.94 30.98
Resistance 2 (R2) 30.94 30.66 30.91 30.92
Resistance 1 (R1) 30.50 30.49 30.36 30.43 30.86
Pivot Point 30.21 30.21 30.14 30.17 30.21
Support 1 (S1) 29.77 29.93 29.62 29.69 29.26
Support 2 (S2) 29.47 29.75 29.44 29.20
Support 3 (S3) 29.03 29.47 29.14
Support 4 (S4) 28.96